ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating

ImaRx Therapeutics, Inc. (Nasdaq: IMRX) announced that the Food and Drug Administration (FDA) has approved the company’s most current lot release request for urokinase drug product. This is the first lot to be released with extended expiration dating. Urokinase, ImaRx’s first commercially available FDA-approved product, is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism.

More: continued here

Filed under: Blood on January 29th, 2008